Access Purchased Content

Addiction Treatment
Addiction Treatment RSS Feed RSS

Research Update

E-Cigarettes for Smoking Cessation: Efficacy and Safety

January 1, 2026
Crystal Obiozor, MD

Crystal Obiozor, MD. Dr. Obiozor has no financial relationships with companies related to this material. 

Compared with counseling alone, e-cigarettes significantly improved six-month smoking abstinence, though many participants continued vaping and did not achieve full nicotine cessation. This study supports e-cigarettes as a valuable tool for smokers who struggle with standard cessation medications.


Read More
Research Update

Does Take-Home Naloxone Lead to Riskier Drug Use?

January 1, 2026
Crystal Obiozor, MD

Crystal Obiozor, MD. Dr. Obiozor has no financial relationships with companies related to this material.

A large prospective cohort study finds no evidence that take-home naloxone increases risky drug use behaviors. Injection frequency, opioid use, benzodiazepine use, and using alone remained unchanged—reinforcing naloxone’s role as a lifesaving harm-reduction tool without unintended risk compensation.


Read More
Fact Sheet

Buprenorphine (Brixadi, Sublocade) Fact Sheet [G]

January 1, 2026
Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder. 


Read More
CATR QA1_Mladen Nisavic_image2_sm.png
Expert Q&A

Phenobarbital for Inpatient Treatment of Alcohol Withdrawal

November 17, 2025
Mladen Nisavic, MD

Mladen Nisavic, MD. Director of Burns and Trauma Psychiatry, Massachusetts General Hospital, Boston, MA. 

Dr. Nisavic has no financial relationships with companies related to this material. 

Dr. Nisavic explains how phenobarbital offers advantages over benzodiazepines for alcohol withdrawal management, particularly in patients with benzodiazepine resistance. He details weight-based loading protocols, monitoring strategies, and the dual GABA/glutamate mechanism that may make phenobarbital superior for severe withdrawal cases.



Read More
CATR_QA2_Craig Gunderson_photo_sm.png
Expert Q&A

Delirium Tremens: Recognition, Risk, and Practical Management

November 17, 2025
Craig Gunderson, MD

Craig Gunderson, MD. Associate Professor of Medicine, Yale University School of Medicine, New Haven, CT. 

Dr. Gunderson has no financial relationships with companies related to this material. 

Dr. Gunderson provides expert guidance on recognizing and managing delirium tremens, challenging conventional wisdom about withdrawal timelines and offering practical approaches to risk stratification. He details his treatment approach for patients at high risk of developing withdrawal complications and discusses the differential diagnosis of delirium in hospitalized patients with alcohol use disorder.


Read More
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.